Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis. Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy).
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 300
- Registration Number
- NCT00854776
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2013-01-03
- Target Recruit Count
- 7
- Registration Number
- NCT00837759
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 366
- Registration Number
- NCT00787254
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
- Conditions
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 461
- Registration Number
- NCT00762359
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 852
- Registration Number
- NCT00701259
- Locations
- 🇺🇸
Not applicable - enrollment complete, Parsippany, New Jersey, United States
Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00685295
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Lansoprazole Versus Mosapride for Functional Dyspepsia
- Conditions
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-10-09
- Lead Sponsor
- Lotung Poh-Ai Hospital
- Target Recruit Count
- 329
- Registration Number
- NCT00663897
- Locations
- 🇨🇳
Lotung Poh-Ai hospital, Lotung Town, Ilan county, Taiwan
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00644735
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00641602
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT00637845
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.